Third Position Detail definition
Third Position Detail means a Detail in which the applicable pharmaceutical product is Detailed in the third position (i.e., no more than two (2) other products are presented to or discussed with the healthcare professional before the Product) and/or the third most predominant portion of time is devoted to the Detailing of such pharmaceutical product.
Third Position Detail means a Detail by an Elan Professional Sales Representative to a Target Healthcare Professional in the Territory in which the Product is Detailed in the third or higher position.
Third Position Detail means a Detail in which the applicable pharmaceutical product is Detailed in the third position (i.e., no more than two other products are presented to or discussed with the healthcare professional before the Profit Share Product) and the third most predominant portion of time is devoted to the Detailing of such pharmaceutical product.
Examples of Third Position Detail in a sentence
For the avoidance of doubt, the foregoing sentence does not prohibit either Party’s Sales Representatives from detailing any product other than a Licensed Product as a Third Position Detail.
More Definitions of Third Position Detail
Third Position Detail means a Detail in which the applicable pharmaceutical product is Detailed in the third position (i.e., no more than two (2) other products are presented to or discussed with the healthcare professional before the Product) and/or the third most predominant portion of time is devoted to the Detailing of such pharmaceutical product. 1.115 “Transition Period” has the meaning set forth in Section 14.5 (Transition Period). 1.116 “United States” or “U.S.” means the United States of America, including its territories and possessions (including the District of Columbia and Puerto Rico). 1.117 “United States Brand Plan” means, with respect to the Product, the United States-specific strategic and high-level tactical, cross-functional Commercialization plan jointly developed by Novartis and Amgen (including through the JUSLT) for the Product in the United States, including the United States Payer Plan and the United States Pricing Policy. 1.118 “United States Novartis Patents and Trademarks” has the meaning set forth in Section 9.2.3 (Novartis Primary Prosecution). 1.119 “United States Patents and Trademarks” has the meaning set forth in Section 9.2.1 (Amgen Primary Prosecution). 1.120 “United States Payer Plan” means, with respect to the Product, the United States-specific plan for the Product jointly prepared by Novartis and Amgen (including through the JUSLT) that sets forth the strategic direction, positioning, value proposition, pricing strategy, value evidence generation plan, economic modeling strategy and reimbursement for the Product in the United States. Amgen Ref. No. 2017747574 Page 13 Note: Redacted portions have been marked with [*]. The redacted portions are subject to a request for confidential treatment that has been filed with the Securities and Exchange Commission. 1.121 “United States Pricing Policy” means, with respect to the Product, the United States-specific plan for the Product jointly prepared by Amgen and Novartis (including through the JUSLT) that sets forth the proposed price range, rebates and discounts range, target population and reimbursement target for the Product in the United States. 1.122 “United States Senior Officers” means the [*] for Novartis and the [*] for Amgen. 1.123 “US Biosimilar Entry Date” has the meaning set forth in Section 8.3.2 (Royalty Reduction for Biosimilar Competition). 1.124 “US Collaboration” has the meaning set forth in Section 2.1 (Conduct of the Collaboration). 1.125 “US Collaboration Team” or “USCT” has t...